Hepatocellular carcinoma enhancement on contrast-enhanced CT and MR imaging: Response assessment after treatment with sorafenib: Preliminary results

Radiologia Medica

Volumn 119, Issue 4, 2014, Pages 215-221

  Salvaggio, Giuseppe ^a   Furlan, Alessandro ^b   Agnello, Francesco ^a   Cabibbo, Giuseppe ^a   Marin, Daniele ^c   Giannitrapani, Lydia ^a   Genco, Chiara ^a   Midiri, Massimo ^a   Lagalla, Roberto ^a   Brancatelli, Giuseppe ^a  

^a UNIVERSITY OF PALERMO   (Italy)

^b UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^c DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

CT; HCC; Liver; MR; Sorafenib

Indexed keywords

CARBANILAMIDE DERIVATIVE; CONTRAST MEDIUM; DIAGNOSTIC AGENT; DRUG DERIVATIVE; GADOBENIC ACID; IOMEPROL; IOPAMIDOL; MEGLUMINE; NICOTINAMIDE; ORGANOMETALLIC COMPOUND; SORAFENIB;

AGED; ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; FEMALE; HUMAN; LIVER CELL CARCINOMA; LIVER TUMOR; MALE; MIDDLE AGED; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOLOGY; RADIOGRAPHY; TREATMENT OUTCOME;

AGED; CARCINOMA, HEPATOCELLULAR; CONTRAST MEDIA; FEMALE; HUMANS; IOPAMIDOL; LIVER NEOPLASMS; MAGNETIC RESONANCE IMAGING; MALE; MEGLUMINE; MIDDLE AGED; NIACINAMIDE; ORGANOMETALLIC COMPOUNDS; PHENYLUREA COMPOUNDS; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 84898031794     PISSN: 00338362     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11547-013-0332-5     Document Type: Article

References (20)

1. Bruix J, Sherman M (2010) Practice Guidelines Committee AASLD. Management of hepatocellular carcinoma: an update. Hepatology 53:1020-1022
2. Roberts LR (2008) Sorafenib in liver cancer - just the beginning. N Engl J Med 359:420-422
3. Llovet JM, Ricci S, Mazzaferro V et al (2008) Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359:378-390
4. Cheng AL, Kang YK, Chen Z et al (2009) Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 10:25-34
5. Sullivan DC, Gatsonis C (2011) Response to treatment series: part 1 and introduction, measuring tumor response - challenges in the era of molecular medicine. AJR Am J Roentgenol 197:15-17
6. Faivre S, Zappa M, Vilgrain V et al (2011) Changes in tumor density in patients with advanced hepatocellular carcinoma treated with sunitinib. Clin Cancer Res 17:4504-4512
7. Eisenhauer EA, Therasse P, Bogaerts J et al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45:228-247
8. Maksimovic O, Schraml C, Hartmann J et al (2010) Evaluation of response in malignant tumors treated with the multitargeted tyrosine kinase inhibitor sorafenib: a multitechnique imaging assessment. AJR Am J Roentgenol 194:5-14
9. Edeline J, Boucher E, Rolland Y et al (2012) Comparison of tumor response by response evaluation criteria in solid tumors (RECIST) and modified RECIST in patients treated with sorafenib for hepatocellular carcinoma. Cancer 118:147-156
10. Smith AD, Lieber ML, Shah SN (2010) Assessing tumor response and detecting recurrence in metastatic renal cell carcinoma on targeted therapy: importance of size and attenuation on contrast-enhanced CT. AJR Am J Roentgenol 194:157-165
11. Yaghmai V, Miller FH, Rezai P et al (2011) Response to treatment series: part 2, tumor response assessment - using new and conventional criteria. AJR Am J Roentgenol 197:18-27
12. Lencioni R, Llovet JM (2010) Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis 30:52-60
13. Horger M, Lauer UM, Schraml C et al (2009) Early MRI response monitoring of patients with advanced hepatocellular carcinoma under treatment with the multikinase inhibitor sorafenib. BMC Cancer 28:208
14. Spira D, Fenchel M, Lauer UM et al (2011) Comparison of different tumor response criteria in patients with hepatocellular carcinoma after systemic therapy with the multikinase inhibitor sorafenib. Acad Radiol 18:89-96
15. Kim KW, Lee JM, Choi BI (2011) Assessment of the treatment response of HCC. Abdom Imaging 36:300-314
16. Choi H, Charnsangavej C, de Castro Faria S et al (2004) CT evaluation of the response of gastrointestinal stromal tumors after imatinib mesylate treatment: a quantitative analysis correlated with FDG PET findings. AJR Am J Roentgenol 183:1619-1628
17. Choi H, Charnsangavej C, Faria SC et al (2007) Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria. J Clin Oncol 25:1753-1759
18. Jiang T, Kambadakone A, Kulkarni NM et al (2012) Monitoring response to antiangiogenic treatment and predicting outcomes in advanced hepatocellular carcinoma using image biomarkers, CT perfusion, tumor density, and tumor size (RECIST). Invest Radiol 47:11-17
19. Sabir A, Schor-Bardach R, Wilcox CJ et al (2008) Perfusion MDCT enables early detection of therapeutic response to antiangiogenic therapy. AJR Am J Roentgenol 191:133-139
20. Wang J, Chen LT, Tsang YM et al (2004) Dynamic contrast-enhanced MRI analysis of perfusion changes in advanced hepatocellular carcinoma treated with an antiangiogenic agent: a preliminary study. AJR Am J Roentgenol 183:713-719